FOLD
AMICUS THERAPEUTICS, INC.
No data for this timeframe.
Vol
Inst. Holders9 funds
Inst. Value$648.6M
Inst. Activity4 buys / 3 sells
Reddit Sentiment60° Warm
SEC Reports3
Recent Activity
May 13, 2026
earnings_calendar
FOLD Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
SEC
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by BioMarin Pharmaceutica
15-12G — Impact 4/10
Apr 27, 2026
SEC
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting fr
8-K — Impact 9/10
Apr 27, 2026
Insider
Campbell Bradley L sold 1,008,680 shares
President and CEO @ $14.50 ($14.6M)
Apr 27, 2026
Insider
Campbell Bradley L sold 103,578 shares
President and CEO @ $0.00 ($0.00)
Apr 27, 2026
Insider
Harford Simon N.R. sold 143,595 shares
Chief Financial Officer @ $14.50 ($2.1M)
Apr 23, 2026
SEC
Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted foreign direct investment cl
8-K — Impact 6/10
Inst.
MORGAN STANLEY — ADD
5,479,689 shares ($78.0M)
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$14.50 (Jan 2026)
Current $14.49
Low $14.50
Median $14.50
High $14.50
5 analysts
$14.50
$14.50
Analyst Ratings
2Strong Buy
4Buy
8Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 22, 2026 | Jefferies | DOWNGRADE | Buy → Hold |
| Dec 29, 2025 | Leerink Partners | DOWNGRADE | Outperform → Market Perform |
| Dec 22, 2025 | Citigroup | DOWNGRADE | Buy → Neutral |
| Dec 19, 2025 | Needham | DOWNGRADE | Buy → Hold |
| Dec 19, 2025 | Cantor Fitzgerald | DOWNGRADE | Overweight → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 ▼ -188.0% | $-0.08 — $-0.08 | -373% YoY | 1 |
| Next Q | $0.02 ▼ -89.6% | $0.02 — $0.02 | 57% YoY | 1 |
| Current FY | $0.07 ▼ -88.8% | $0.07 — $0.07 | -77% YoY | 1 |
| Next FY | $0.82 ▼ -10.8% | $0.47 — $0.97 | 1029% YoY | 4 |
Latest Reports
NEUTRAL
15-12G
4/10
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by BioMarin Pharmaceutica
May 7, 2026
NEUTRAL
8-K
9/10
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting fr
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $423.0M | — |
| MORGAN STANLEY | $78.0M | ADD |
| BANK OF AMERICA CORP | $49.0M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $36.5M | NEW |
| TWO SIGMA INVESTMENTS, LP | $21.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 27, 2026 | Campbell Bradley | D | $14.6M |
| Apr 27, 2026 | Campbell Bradley | D | $0.00 |
| Apr 27, 2026 | Harford Simon | D | $2.1M |
| Apr 27, 2026 | Harford Simon | D | $0.00 |
| Apr 27, 2026 | Castelli Jeff | D | $6.2M |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
9 institutional holders with $648.6M total value (45,550,299 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 4 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 29,702,696 | $423.0M | 65.2% | — |
| 2 | MORGAN STANLEY | 5,479,689 | $78.0M | 12.0% | ADD +71.3% |
| 3 | BANK OF AMERICA CORP /DE/ | 3,438,241 | $49.0M | 7.5% | TRIM -51.7% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,561,753 | $36.5M | 5.6% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 1,473,341 | $21.0M | 3.2% | ADD +51.1% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1,211,693 | $17.3M | 2.7% | TRIM -37.6% |
| 7 | NORGES BANK | 1,165,028 | $16.6M | 2.6% | NEW |
| 8 | WELLS FARGO & COMPANY/MN | 339,426 | $4.8M | 0.7% | ADD +76.3% |
| 9 | FMR LLC | 178,432 | $2.5M | 0.4% | TRIM -64.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 3,198,670 | 5,479,689 | +71.3% | $78.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 7,117,070 | 3,438,241 | -51.7% | $49.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 974,875 | 1,473,341 | +51.1% | $21.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,943,171 | 1,211,693 | -37.6% | $17.3M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,165,028 | — | $16.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 192,503 | 339,426 | +76.3% | $4.8M | 2025-Q4 |
| FMR LLC | TRIM | 503,773 | 178,432 | -64.6% | $2.5M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 4,292,362 | 3,198,670 | -25.5% | $25.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 732,735 | 974,875 | +33.0% | $7.7M | 2025-Q3 |
| NORGES BANK | EXIT | 3,235,538 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 2,428,134 | 4,292,362 | +76.8% | $24.6M | 2025-Q2 |
| NORGES BANK | NEW | — | 3,235,538 | — | $18.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,561,993 | 2,013,593 | +28.9% | $11.5M | 2025-Q2 |
| UBS Group AG | ADD | 1,336,871 | 1,693,292 | +26.7% | $9.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,392,769 | 732,735 | -47.4% | $4.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,108,616 | 1,561,993 | -25.9% | $12.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 297,443 | 1,392,769 | +368.2% | $11.4M | 2025-Q1 |
| FMR LLC | ADD | 270,951 | 386,895 | +42.8% | $3.2M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 439,471 | 164,718 | -62.5% | $1.3M | 2025-Q1 |
| NORGES BANK | EXIT | 3,082,036 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 3,717,263 | 8,296,249 | +123.2% | $78.2M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 4,215,331 | 2,121,668 | -49.7% | $20.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 769,300 | 2,108,616 | +174.1% | $19.9M | 2024-Q4 |
| UBS Group AG | ADD | 563,972 | 1,080,031 | +91.5% | $10.2M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,667,271 | — | $28.5M | 2024-Q3 |
14 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Campbell Bradley L | President and CEO | D | 1,008,680 | $14.50 | $14.6M |
| Apr 27, 2026 | Campbell Bradley L | President and CEO | D | 103,578 | $0.00 | $0.00 |
| Apr 27, 2026 | Harford Simon N.R. | Chief Financial Officer | D | 143,595 | $14.50 | $2.1M |
| Apr 27, 2026 | Harford Simon N.R. | Chief Financial Officer | D | 189,043 | $0.00 | $0.00 |
| Apr 27, 2026 | Castelli Jeff | Chief Development Officer | D | 427,089 | $14.50 | $6.2M |
| Apr 27, 2026 | Castelli Jeff | Chief Development Officer | D | 82,644 | $0.00 | $0.00 |
| Apr 27, 2026 | Clark David Michael | Chief People Officer | D | 221,811 | $14.50 | $3.2M |
| Apr 27, 2026 | Clark David Michael | Chief People Officer | D | 84,842 | $0.00 | $0.00 |
| Apr 27, 2026 | Rosenberg Ellen | Chief Legal Officer | D | 463,898 | $14.50 | $6.7M |
| Apr 27, 2026 | Rosenberg Ellen | Chief Legal Officer | D | 93,663 | $0.00 | $0.00 |
| Apr 27, 2026 | Prout Samantha | Chief Accounting Officer | D | 125,951 | $14.50 | $1.8M |
| Apr 27, 2026 | Prout Samantha | Chief Accounting Officer | D | 2,526 | $0.00 | $0.00 |
| Apr 27, 2026 | RAAB MICHAEL | Director | D | 115,857 | $14.50 | $1.7M |
| Apr 27, 2026 | RAAB MICHAEL | Director | D | 20,000 | $0.00 | $0.00 |
| Apr 27, 2026 | Kelly Michael Aaron | Director | D | 72,468 | $14.50 | $1.1M |
| Apr 27, 2026 | Kelly Michael Aaron | Director | D | 36,111 | $0.00 | $0.00 |
| Apr 27, 2026 | Bleil Lynn Dorsey | Director | D | 113,941 | $14.50 | $1.7M |
| Apr 27, 2026 | Bleil Lynn Dorsey | Director | D | 14,605 | $0.00 | $0.00 |
| Apr 27, 2026 | ROBERTS EIRY | Director | D | 76,275 | $14.50 | $1.1M |
| Apr 27, 2026 | ROBERTS EIRY | Director | D | 40,625 | $0.00 | $0.00 |
| Apr 27, 2026 | SBLENDORIO GLENN | Director | D | 142,564 | $14.50 | $2.1M |
| Apr 27, 2026 | SBLENDORIO GLENN | Director | D | 20,000 | $0.00 | $0.00 |
| Apr 27, 2026 | WHITMAN BURKE W | Director | D | 118,598 | $14.50 | $1.7M |
| Apr 27, 2026 | WHITMAN BURKE W | Director | D | 25,964 | $0.00 | $0.00 |
| Apr 27, 2026 | MCGLYNN MARGARET G | Director | D | 94,631 | $14.50 | $1.4M |
| Apr 27, 2026 | MCGLYNN MARGARET G | Director | D | 20,000 | $0.00 | $0.00 |
| Apr 27, 2026 | WHEELER CRAIG A | Director | D | 84,631 | $14.50 | $1.2M |
| Apr 27, 2026 | WHEELER CRAIG A | Director | D | 30,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 6.3/10.
NEUTRAL
15-12G
4/10
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by Bi
May 7, 2026
NEUTRAL
8-K
9/10
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of c
Apr 27, 2026
NEUTRAL
8-K
6/10
Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted foreign
Apr 23, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2026): 43% buy across 14 analysts — 2 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$14.50 mean target (Jan 2026)
$14.50 Low
$14.50 High
| Metric | Value |
|---|---|
| Current Price | $14.49 |
| Target Low | $14.50 |
| Target Mean | $14.50 |
| Target Median | $14.50 |
| Target High | $14.50 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.08 | $-0.08 | $-0.08 | -372.8% | -188.0% | 0↑ 1↓ | $0.2B | 27.5% | 1 |
| Next Q 2026-06-30 |
$0.02 | $0.02 | $0.02 | 57.1% | -89.6% | 0↑ 1↓ | $0.2B | 16.9% | 1 |
| Current FY 2026-12-31 |
$0.07 | $0.07 | $0.07 | -76.6% | -88.8% | 0↑ 1↓ | $0.8B | 18.6% | 1 |
| Next FY 2027-12-31 |
$0.82 | $0.47 | $0.97 | 1028.8% | -10.8% | 0↑ 1↓ | $0.9B | 18.1% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.082 | |
| 7d ago | $0.093 | -0.175 |
| 30d ago | $0.093 | -0.175 |
| 60d ago | $0.093 | -0.175 |
| 90d ago | $0.093 | -0.175 |
5 analyst firms have rated this stock: 0 upgrades, 5 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 22, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Dec 29, 2025 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Dec 22, 2025 | Citigroup | DOWNGRADE | Buy | Neutral |
| Dec 19, 2025 | Needham | DOWNGRADE | Buy | Hold |
| Dec 19, 2025 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Dec 17, 2025 | Citigroup | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Apr 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Mar 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Feb 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Jan 1, 2026 | 4 | 4 | 6 | 0 | 0 | 57% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Dec 7, 2024 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 13, 2026
earnings_calendar
FOLD Q1 2026 Earnings Scheduled — 2026-05-13
Apr 29, 2026
earnings_calendar
FOLD Q1 2026 Earnings Scheduled — 2026-04-29
Apr 24, 2026
short_volume
Short Volume: FOLD — 73.2% short (1.2M / 1.6M)
Short: 1,179,258 | Exempt: 0 | TRF Vol: 1,610,688 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: FOLD — 55.4% short (0.4M / 0.8M)
Short: 428,660 | Exempt: 0 | TRF Vol: 773,686 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: FOLD — 72.9% short (0.4M / 0.5M)
Short: 385,537 | Exempt: 0 | TRF Vol: 528,804 | Short Ratio: 72.9% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: FOLD — 55.2% short (0.4M / 0.7M)
Short: 370,260 | Exempt: 4,000 | TRF Vol: 670,794 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: FOLD — 510,028 shares ($7.4M) failed to deliver
Settlement: 20260406, Price: $14.44, FTD Value: $7,364,804.32, AMICUS THERAPEUTICS INC COM ST
Mar 30, 2026
Clinical Trial
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Cipaglucosidase Alfa (Phase 3)
Trial: ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
Sponsor: Amicus Therap
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Cipaglucosidase Alfa (Phase 3)
Trial: ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
Sponsor: Amicus Therap
Mar 27, 2026
short_volume
Short Volume: FOLD — 56.8% short (0.4M / 0.6M)
Short: 368,807 | Exempt: 0 | TRF Vol: 649,158 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Feb 9, 2026
short_interest
FTD: FOLD — 6,681,911 shares ($95.6M) failed to deliver
Settlement: 20260209, Price: $14.30, FTD Value: $95,551,327.3, AMICUS THERAPEUTICS INC COM ST